Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy.

Andrew M. Demchuk,Patrick Yue,Elena Zotova,Juliet Nakamya,Lizhen Xu,Truman J. Milling,Tomoyuki Ohara,Joshua N. Goldstein,Saskia Middeldorp,Peter Verhamme,Jose Lopez-Sendon,Pamela B. Conley,Curnutte John T,John W. Eikelboom,Mark Crowther,Stuart J. Connolly,Annexa Investigators

Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy.

2021

Andrew M. Demchuk
Patrick Yue
Elena Zotova
Juliet Nakamya
Lizhen Xu
Truman J. Milling
Tomoyuki Ohara
Joshua N. Goldstein
Saskia Middeldorp
Peter Verhamme
Jose Lopez-Sendon
Pamela B. Conley
Curnutte John T
John W. Eikelboom
Mark Crowther
Stuart J. Connolly
Annexa Investigators

Background and Purpose: Andexanet alfa is a recombinant modified human FXa (factor Xa) developed to reverse FXa inhibition from anticoagulants. Hemostatic efficacy and reversal of anti-FXa activity...

Keywords:

anti fxa
Pharmacology
Recombinant DNA
Andexanet alfa
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations